Incyte Expands Skin Diseases Treatment Partnership in Australia
MT Newswires Live
Sep 21
Incyte's (INCY) affiliate expanded its partnership with Specialised Therapeutics to commercialize, distribute and register ruxolitinib cream in Australia, Specialised Therapeutics said Sunday.
The company said Ruxolitinib cream is approved in Australia to treat non-segmental vitiligo in adults and children ages 12 and older, and mild-to-moderate atopic dermatitis in adults and children ages 2 and older.
Under the agreement, Specialised Therapeutics said Incyte will continue to handle development and manufacturing, while it will oversee regulatory submissions, medical affairs, marketing and distribution in Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.